• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 67
  • 12
  • 6
  • 6
  • 6
  • 6
  • 6
  • 6
  • 4
  • 4
  • 2
  • 1
  • Tagged with
  • 109
  • 109
  • 54
  • 35
  • 34
  • 23
  • 19
  • 16
  • 14
  • 13
  • 12
  • 11
  • 11
  • 11
  • 11
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
61

Mecanismos anti-proliferativos disparados por FGF2 e éster de forbol em células de camundongos tranformadas por Ras / Anti-proliferative mechanisms induced by FGF2 and phorbol ester in murine cell lines transformed by Ras

Tatiana Guimarães de Freitas Matos 17 September 2007 (has links)
Mutações com ganho de função do proto-oncogene Ras se encontram entre umas das mais freqüentes modificações em cânceres humanos, além disso, tumores com esses caracterísitcas possuem, em geral, mau prognóstico. O objetivo inicial desta tese foi estudar novos mecanismos anti-proliferativos disparados por dois agentesmitogênicos, FGF2 (\"Fibroblast Growth Factor 2\") e PMA (\"Phorbol-12-Myristate-13-Acetate\", (um diéster de forbol), sobre células de camundongos transformadas por Ras e refratárias a apoptose. Para isso utilizamos duas linhagens celulares: uma linhagem naturalmente trtansformada por uma ampliação do gene K-Ras, que é derivada de um tumor de córtex adreno-cortical de camundongo e é denominada Y1, e uma sublinhagem derivada de Balb/c-3T3, transformada em laboratório com o oncogene H-RasV12 humano. A fim de se elucidar o mecanismo de ação de FGF2, foram selecionadas e caracterizadas múltiplas sublinhagens clonais resistentes a FGF2, derivadas das linhagens parentais Y1 e B61. Mostramos assim, que o FGF2 exerce um forte efeito negativo, de forma que os clones resistentes ao mesmo tendem a perder aos altos níveis de expressão da proteína Ras. Mostramos ainda que esses células passam a ser dependentes de FGF2 para crescer em cultura, perdem a capacidade de crescimento em suspensão e são menos tumorigênicas quando comparadas às células parentais. Em uma segunda etapa, caracterizamos o efeito citotóxico de PMA sobre células transformadas por Ras, e vimos que esse efeito é mais acentuado para células transformadas por K-Ras, mas é nulo sobre células imortalizadas não tumorigênicas. Mostramos ainda que esse efeito passa pela ativação da via de PKC. A inibição da proliferação por PMA se deve, ao menos parcialmente, à indução de senescência nessas células. De forma semelhante ao que foi para o estudo com FGF2, foram selecionados clones resistentes a PMA, derivados de Y1. Os clones obtidos se mostraram muito instáveis, pouco resistentes a PMA e dependentes de FGF2 para crescer. Todos os clones testados se mostram tumorigênicos, entretanto, apresentaram maior tempo de latência, estaticamente diferente da célula parental, Y1. Assim, neste trabalho, mostramos que duas substâncias, com caráter mitogênico e potencialmente oncogênico, são capazes de inibir seletivamente a proliferação de células transformadas por Ras, uma vez que elas não têm efeito sobre células não transformadas. Desvendar os mecanismos que causam a citotoxidade dessas substâncias deve trazer informações relevantes com possibilidades de impacto em terapia de tumores dependentes dos oncogenes Ras. / Amplification and gain of function mutations in ras proto-oncogenes are frequent genetic lesions in human cancers of bad prognostic. This thesis aimed to investigate novel anti-proliferative mechanisms induced by two mitogens, FGF2 (\"Fibroblast Growth Factor 2\") and PMA (\"Phorbol-12-Myristate-13-Acetate\", a phorbol diester), in murine cell lines transformed by ras and resistant to apoptosis. To this end, we took two different mouse malignant cell lines: Y1, a cell line derived from an adrenal tumor, naturally transformed by K-ras amplification and another one, 3T3-B61, obtained by transformation of Balb-3T3 fibroblasts with the H-rasV12 oncogene. To elucidate FGF2 mechanisms of action, we selected, isolated and characterized clonal sublines resistant to FGF2 from both Y1 and 3T3-B61 parental lines. FGF2-resistant clones are rare normal-like revertant sublines that no longer display Ras over expression, dependent on FGF2 for growth, do not grow in suspension cultures and exhibit low tumorigenicity in Nude mice. These results show that FGF2 exerts a strong selective pressure against ras-transformed cells, inducing senescence and irreversibly blocking proliferation. Differently from FGF2 , PMA citotoxic effect is completely dependent on PKC activity. In addition, PMA is highly toxic to K-Ras transformed Y1 cells, poorly toxic to H-Ras-transformed 3T3-B61 cells and not toxic to immortalized non tumorigenic cell lines. Attempts to select PMA-resistant cells fropm Y1 parental line have yielded very rare, highly clonal sublines, dependent on FGF2 for proliferation. In conclusion, two mitogens, FGF2 and PMA, can selectively inhibit Ras-driven proliferation, a phenomenon of great interest for biology and therapy of tumors dependent on ras oncogenes.
62

Efeito da cisplatina em cultura de linhagens estabelecidas e sua capacidade de induzir transformação celular in vitro / Effesct of cisplatin on culture cell lines and its ability to induce cellular transformation in vitro

Gonçalves, Estela Maria 20 December 2005 (has links)
Orientador: Selma Candelaria Genari / Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-05T19:22:08Z (GMT). No. of bitstreams: 1 Goncalves_EstelaMaria_D.pdf: 4512893 bytes, checksum: 36b5b4604b23f405a7254a71f5971cd4 (MD5) Previous issue date: 2005 / Resumo: A cisplatina é um agente antineoplásico utilizado no tratamento quimioterápico de tumores como os de testículo, de ovário e de bexiga urinária. Contudo, estudos indicam que a cisplatina apresenta potencial mutagênico, genotóxico e tumorigênico tanto in vitro como in vivo. Após tratamento com 50 µg/ml de cisplatina durante 24 h, células Vero apresentaram alterações comportamentais e morfológicas associadas à transformação celular in vitro. Modificações morfológicas foram investigadas com utilização de imunocitoquímica (fibronectina), microscopia eletrônica de varredura e coloração faloidina-fluoresceína (actina). O estudo proliferativo foi realizado a partir de curvas de crescimento e o padrão de adesão celular foi obtido através de testes de adesão. Características citogenéticas foram avaliadas em células Vero e V79 tratadas com cisplatina, através da determinação dos números modais de cromossomos, das freqüências de poliploidia e dos índices mitóticos. Células Vero controles apresentaram crescimento em monocamadas, enquanto que células Vero transformadas cresceram em múltiplas camadas, formando grumos ou agregados celulares. A proliferação celular e as características morfológicas e de adesão das células Vero transformadas foram acentuadamente diferentes das células controles. Células Vero transformadas e células V79 tratadas com cisplatina apresentaram alterações nos números de cromossomos além de aumento nos índices mitóticos e nas freqüências de poliploidia. Os resultados obtidos indicam que as alterações morfológicas, de crescimento e de adesão observadas em células Vero e as alterações citogenéticas, observadas em células Vero e em células V79, provavelmente relacionam-se com a transformação celular in vitro induzida pelo tratamento com cisplatina. Estas células Vero transformadas apresentam características associadas ao crescimento neoplásico, podendo ser utilizadas como modelo de estudo de células tumorais in vitro / Abstract: Cisplatin is an antineoplastic agent used to treat solid malignancies, such as testicular, ovarian and bladder tumors. However, both in vitro and in vivo, cisplatin has been shown to be mutagenic, genotoxic and tumorigenic. Maintained in culture, Vero cells presented behavioral and morphological alterations associated with cellular transformation in vitro, after treatment with 50 µg/ml of cisplatin during 24 h. The morphological alterations were investigated using immunocytochemistry (fibronectin), scanning electron microscopy and the actin cytoskeleton was labeling with fluorescein isothiocyanate-phalloidin. The study of proliferation was obtained from the growth curve and the adhesion pattern was obtained from the adhesion assay. In Vero and V79 cells treated with cisplatin, cytogenetical characteristics were obtained by modal chromosome numbers, polyploidy frequencies and mitotic index determinations. Control Vero cells presented growth in a monolayer, while the transformed cells grew in multilayers forming cellular aggregates. The cellular proliferation, adhesion pattern and morphological characteristics of the transformed Vero cells were very different from the control ones. Transformed Vero cells and cisplatin-treated V79 cells presented altered chromosome numbers. Polyploidy frequencies and mitotic indexes were also enhanced in these cells. The results indicate that morphological, growth and adhesion changes observed in Vero cells and cytogenetical alterations, observed in Vero and V79 cells, probably resulted from cellular transformation in vitro induced by cisplatin treatment. These transformed Vero cells presented characteristics associated with neoplastic growth, and can be used as a model for tumor cells studies in vitro / Doutorado / Biologia Celular / Doutor em Biologia Celular e Estrutural
63

The Cellular Immune Response to Epstein-Barr Virus during Active Infectious Mononucleosis: a Thesis

Tomkinson, Blake E. 01 June 1988 (has links)
Epstein-Barr virus (EBV) induced infectious mononucleosis (IM) is characterized by the activation and expansion of T lymphocytes and the induction of cytotoxic responses able to mediate the lysis of EBV-uninfected, allogeneic MHC mismatched and EBV-infected autologous target cells. Freshly isolated peripheral blood mononuclear cells (PBMC) were used to examine the nature of these cellular immune responses. Activated lymphocytes, as identified by HLA-DR expression, associated with EBV induced IM were shown to be a heterogeneous population containing significantly elevated cytotoxic/suppressor (CD8+) T cells, helper/inducer (CD4+) T cells and natural killer (NK, CD16+) cells. CD8+ T cells were the primary activated population, representing 24% of the total lymphocyte population and 60-70% of the CD8+ T cell population. The activated CD4+ T cells and natural killer (NK) cells accounted for 7% and 4% of the total lymphocyte population, respectively. Analysis of serum soluble interleukin 2 receptors (IL-2R) and CD8 molecules demonstrated significantly (p<0.001) elevated levels in the sera of IM patients compared with normal controls. These elevated levels of serum IL-2R am CD8 molecules correlated, (r=0. 67 and r=0.82, respectively) with increased percentages of CD8/HLA-DR positive T cells (i.e., activated CD8 T cells). Increased levels of soluble cell surface molecules peaked during the acute phase and normalized as the patients progressed toward convalescence. Individual patients demonstrated strong correlations between the percentage of CD8/HLA-DR positive cells and soluble CD8 levels. The functional significance of the serum IL-2R and CD8 molecules is presently unknown. However, the strong correlative data between serum CD8, and to a lesser extent IL-2R, and CD8 T cell activation suggests that serum CD8 levels may provide a sensitive measure of CD8 T cell activation in systemic infections. The ability of freshly isolated acute IM PBMC to lyse allogeneic, EBV-infected lymphoblastoid cell lines (LCL), demonstrated the ability of acute IM effector cells to lyse MHC mismatched target cells. Effector cells from acute IM patients lysed allogeneic DM-LCL and AF-LCL target cells by 34% (n=7) and 23% (n=6), respectively, compared with 4% (n=5) and 0% (n=5), respectively, for normal controls. MAb-dependent complement depletion of CD3+ or CD8+ cells with anti-CD3 and anti-CD8 mAb decreased the non-MHC restricted cytolysis of LCL by 96% and 89%, respectively. In contrast, complement depletion with NK-cell specific mAbs Leu 11b and NKH-1, resulted in only a slight decrease (<35%) in the lysis of these LCL (46%). Depletion with anti-HLA-DR also significantly (p<0.001) decreased the lysis of LCL. Depletions with anti-CD4 demonstrated no decrease in LCL-lysis. MAbs OKT3 and OKT8 inhibited the non-MHC restricted cytolysis by 87% and 82%, respectively. We interpret these results as evidence that, 1) lysis of allogeneic cells is mediated primarily by CD3+, CD8+, HLA-DR+, cytotoxic T lymphocytes (CTL); and 2) these acute IM cytotoxic T cells utilize the T cell receptor and the CD8 antigen as an accessory molecule. An active role for target cell MHC class I molecules in the recognition and subsequent lysis of target cells is supported by a number of observations: 1) the MHC class I reactive mAbs W6/32 and BBM.1 significantly (p<0.05) inhibited the lysis of 63463-LCL by 65% and 57%, respectively; 2) acute IM effector T cells did not lyse the MHC class I negative Daudi cell line; 3) allogeneic MHC class I matched LCL mediated strong competitive inhibition (72% at 10:1 competitor to target cell ratio) vs 29% competitive inhibition for an allogeneic MHC class I mismatched LCL; and 4) NK-cell depleted effector cells from one patient mediated preferential lysis of the K562 cell line expressing MHC class I. HLA-A2 molecules. We interpret these results as evidence that target cell MHC class I molecules (or associated determinants) are the target antigen(s) for the allogeneic MHC cytotoxic response. The role of EBV in this acute allogeneic response was examined using target cell lines devoid of EBV genome. Acute IM CTL mediated lysis of the allogeneic HSB-2 T cell line (45%), and allogeneic HTLV-I transformed T cell lines (16%). The lysis of the HSB-2 T cell line was inhibited by anti-OKT3 (58% inhibition), W6/32 (53%) and BBM.1 (42%). Similarily, lysis of HTLV-I T cell lines was inhibited by W6/32 (69% inhibition), BBM.1 (69%) and OKT3 (38%). These data demonstrate that EBV antigenic expression is not required for allogeneic recognition and subsequent lysis of these allogeneic target cells. Effector cells from acute IM patients (n=5) were able to lyse their autologous EBV-infected LCL (mean lysis=21%), but were unable to lyse the EBV-uninfected autologous HTLV-I T cell line. These same effectors, however, were able to mediate lysis of both allogeneic B cell lines (21% lysis) and allogeneic T cell lines (8% lysis). These data are consistent with the observations by Strang et al. (1987a), who recently cloned virus specific/MHC-restricted CTL cloned from acute IM PBMC. These virus specific/MHC-restricted T cells presumably mediate the lysis of the autologous EBV-transformed B cell lines but not the autologous EBV-uninfected T cell lines. Whether the CTL which lyse the autologous EBV-transformed LCL are also responsible for the observed allogeneic reactivity was examined with cold target competition using autologous and allogeneic LCL. Lysis of autologous LCL was inhibited only by autologous competitor cells (64% inhibition compared with 24% for allogeneic LCL). Likewise, lysis of the allogeneic LCL was inhibited only by the allogeneic competitor cells (85% inhibition compared with 30% for autologous LCL). These data demonstrated no competition between allogeneic and autologous LCL and therefore support the concept that lysis of autologous LCL and allogeneic target cells is mediated by distinct effector populations. These data help us to understand the unusual immune response observed during acute IM. The strong allogeneic cytotoxic response is thought to represent polyclonal CD8 T cell activities induced by EBV-infected and transformed B cells which circulate in vivo. In addition, a population of CD8 CTL exist which mediate the lysis of autologous EBV-transformed B cells. These CTL likely represent virus-specific/MHC-restricted CTL and presumably play a major role in the control of EBV infections. The role, if any, of the markedly expanded alloreactive CTL population in the elimination of EBV infected and transformed B cells remains to be clarified.
64

Expression of the Class II Antigen-Associated Invariant Chain in Leukemic and Virally Transformed Cells

Spiro, Robert Christopher 01 August 1984 (has links)
The objective of this study was to identify possible roles of the class II antigen-associated, electrophoretically invariant chain (Ii) in class II antigen functions through analysis of the kinetics of synthesis, processing, and turnover of Ii in various cellular systems of Ii hyperexpression. Using [35S]methionine metabolic labeling of microsomal membrane proteins and analysis in one-dimensional SDS polyacrylamide gradient gels and two-dimensional electrophoretic gels, enhanced expression of Ii was demonstrated in leukemic cells of a subset of patients with hairy cell leukemia (HCL), in normal peripheral blood cells freshly transformed with EBV, and in Burkitt's lymphoma cell lines treated with n-butyrate. As part of an initial effort to identify leukemic cell subset-defining, membrane-associated molecules which might then be tested as targets for, or regulators of, the anti-leukemic cell immune response, subsets of HCL patients were identified on the basis of leukemic cell enhanced expression of 35,000 and 15,000 dalton proteins (p35 and p15). A similar enhanced expression of the p35 molecule was demonstrated in peripheral blood or cord blood lymphocytes freshly transformed with Epstein-Barr virus (EBV), as compared to long-term cultured EBV cell lines. Further structural characterization of the HCL p35 by one-dimensional SDS-PAGE and two-dimensional gel electrophoresis of HCL total microsomal membrane proteins, anti-class II antigen immunoprecipitates, and anti-Ii immunoprecipitates showed that the HCL p35 molecule was the human class II antigen-associated Ii chain. In order to determine the functional significance of altered Ii expression on class II antigen function, the relative kinetics of Ii synthesis, processing, and turnover was examined in an in vitro model system of regulated Ii synthesis. Treatment of the Burkitt's lymphoma cell line, Jijoye, and its class II antigen-negative, mutant, daughter cell line, P3HR-1, with 4 mM n-butyrate for 48 hr, enhanced the rate of synthesis of the Ii chain. One-dimensional SDS-PAGE and two-dimensional gel, electrophoretic analysis of anti-Ii and anti-class II antigen immunoprecipitates isolated from pulse-/pulse-chase-/or continuously labeled, control and butyrate-treated P3HR-1 and Jijoye cells demonstrated enhanced levels of synthesis of the dominant, most basic form of Ii in the butyrate-treated samples (to a greater degree in Jijoye cells). The butyrate enhancement of Ii synthesis occurred in the presence or absence of detectable class II alpha and beta chains, as did the relative turnover, although the terminal processing of Ii to an electrophoretically slower and more acidic form was dependent upon its association with class II antigens. The level of the dominant, most basic form of Ii expressed in the hairy leukemic cells equaled that in butyrate-treated Jijoye cells. However, hairy leukemic cell, class II antigen-associated Ii was not terminally processed. The results of these experiments were consistent with the following. In lymphoblastoid cells, two pathways for Ii turnover might exist. One is through association with class II antigen complexes and progressive carbohydrate-chain terminal processing, and a second is not associated with class II antigens and such processing. Class II antigens may direct the processing of Ii towards some function (rather than vice versa). Butyrate treatment rather uniquely enhances the synthesis of Ii in some lymphoid cells in the presence or absence of class II antigens. Hairy leukemic cells demonstrate an inability to terminally process Ii which might be relevant to the function of Ii and/or class II antigens on those cells.
65

The effects of aging and transformation on the DNA, RNA, protein, and hydroxyproline content of fibroblasts (WI 38) in culture

Eichner, James Michael 01 January 1973 (has links) (PDF)
The study of the aging process is the investigation as to how the passage of time affects cells, organs, and organisms. Aging is a very complex and incompletely understood phenomenon. This is reflected by the number of theories attributing aging to a variety of causative factors such as: (1) the somatic mutations occurring spontaneously or produced by ionizing radiation, which are thought to have some effect on again but are not responsible for the normal process; (2) the alteration of macromolecules as the cells of an organism age forming neoantigens and functioning in the autoimmune reactions; the Cross-linkage theory which maintains that large molecules necessary for life processes, such as deoxyribonucleic acid (DNA) and collagen are progressively immobilized in all cells and tissues by cross-linkage. Aging has also been studied in relation to the self-destructive “programmed death” characteristic of some parts of embryological development. Moreover, senescent changes involve different kinds of cells and tissues in the organism and therefore various mechanisms must occur. For example, the aging of postmitotic cells, such as neurons and cardiac cells probably proceeds by a different mechanism than the proliferating tissues, such as the skin, the gut lining, and the blood forming elements. It is apparent that there is probably no single aging process, but a series of aging processes which natural selection would tend to synchronize even if the causes were physiologically independent.
66

Targeting L-Arginine Metabolism to Control Small Cell Lung Cancer Transformation

Burns, Robert L, Jr. 01 January 2022 (has links) (PDF)
Cancer is known for its unregulated and mutagenic characteristics. The topic of targeting cancer by inhibiting the metabolic pathways it uses to thrive has been a focus of modern cancer research. Specifically, in lung cancer, the transformation from non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is a focus. This transformation often comes with a grimmer prognosis and reduced survival rate. This is primarily due to SCLC being resistant to epidermal growth factor receptor (EGFR) inhibitors. This frontline treatment for EGFR mutant NSCLC has shown to be quite effective until transformation to SCLC occurs. To further study the metabolic factors responsible for this transformation, a metabolic screening was conducted on SCLC transformed lung tissues and tumor adjacent normal lung tissues. This analysis revealed that the amino acid L-arginine and intermediates in its biosynthetic pathway were severely dysregulated. While L-arginine supplementation has shown to inhibit the growth of breast and colorectal cancers, there is little literature about its effects on lung cancer. Using cell viability and gene expression screening tools, we have identified arginine metabolizing genes ARG2, GATM, and OAT as being upregulated in NSCLC treated with high concentrations of an EGFR inhibitor. These high treatments also correlate with increased expression of neuronal differentiation factor 1 (NEUROD1), which has been shown to drive tumorigenesis, metastasis, and SCLC transformation. These findings show a role for altering arginine metabolism to accomplish drug resistance through SCLC transformation. These findings will hopefully pave the way for later clinical use of arginine converting enzymes and NEUROD1 expression levels as predictive markers of early drug resistance and SCLC transformation.
67

Comparative Studies on molecular mechanisms utilized by HTLV-1 and HTLV-2 in viral replication and induction of T-cell transformation

Xie, Li 14 July 2005 (has links)
No description available.
68

Subtle Controllers: MicroRNAs Drive Pancreatic Tumorigenesis and Progression: A Dissertation

Quattrochi, Brian J. 13 April 2015 (has links)
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal malignancies in the United States, with an average five-year survival rate of just 6.7%. One unifying aspect of PDAC is mutational activation of the KRAS oncogene, which occurs in over 90% of PDAC. Therefore, inhibiting KRAS function is likely an effective therapeutic strategy for this disease, and current research in our lab and others is focused on identifying downstream effectors of KRAS signaling that may be therapeutic targets. miRNAs are powerful regulators of gene expression that can behave as oncogenes or tumor suppressors. Dysregulation of miRNA expression is commonly observed in human tumors, including PDAC. The mir-17~92 cluster of miRNAs is an established oncogene in a variety of tumor contexts, and members of the mir-17~92 cluster are upregulated in PDAC, but their role has not been explored in vivo. This dissertation encompasses two studies exploring the role of miRNAs in pancreatic tumorigenesis. In Chapter II, I demonstrate that deletion of the mir-17~92 cluster impairs PDAC precursor lesion formation and maintenance, and correlates with reduced ERK signaling in these lesions. mir-17~92 deficient tumors and cell lines are also less invasive, which I attribute to the loss of the miR-19 family of miRNAs. In Chapter III, I find that Dicer heterozygosity inhibits PDAC metastasis, and that this phenotype is attributable to an increased sensitivity to anoikis. Ongoing experiments will determine whether shifts in particular miRNA signatures between cell lines can be attributed to this phenotype. Together these findings illustrate the importance of miRNA biogenesis, and the mir-17~92 cluster in particular, in supporting PDAC development and progression.
69

Autophagy-Independent Role for Beclin 1 in the Regulation of Growth Factor Receptor Signaling: A Dissertation

Rohatgi, Rasika 15 January 2015 (has links)
Beclin 1 is a haplo-insufficient tumor suppressor that is decreased in many human tumors. The function of Beclin 1 in cancer has been attributed primarily to its role in the degradative process of autophagy. However, the role of autophagy itself in tumorigenesis is context-dependent and can be both preventive and promoting. Due to its dual function in cancer a better understanding of this process is necessary to develop potential novel cancer therapies. To gain insight into the role of autophagy in breast carcinoma, I analyzed the autophagydependency of different subtypes of breast cancer. My results implicate that triple-negative breast carcinoma cells are more dependent on autophagy than luminal breast carcinoma cells. Chemical inhibition of autophagy decreased the tumorigenicity of triple-negative breast carcinoma cells with regard to proliferation and anchorage-independent growth. However, RNAi-mediated suppression of two autophagy genes, ATG5 and Beclin 1, revealed different outcomes. While suppression of ATG5 decreased glycolysis, Beclin 1 depletion did not affect the glycolytic rates. These results suggest autophagy-independent pro-tumorigenic effects of loss of Beclin 1 in cancer. Beclin 1 is a core component of the Vps34/Class III PI3K (PI3KC3) and Vps15/p150 complex that regulates multiple membrane trafficking events. I describe a novel mechanism of action for Beclin 1 in breast cancer involving its control of growth factor receptor signaling. I identify a specific stage of early endosome maturation that is regulated by Beclin 1, the transition of APPL1- containing phosphatidyIinositol 3-phosphate-negative (PI3P-) endosomes to PI3P+ endosomes. Beclin 1 regulates PI3P production in response to growth factor stimulation to control the residency time of growth factor receptors in the PI3P-/APPL+ signaling competent compartment. As a result, suppression of BECN1 sustains growth factor stimulated AKT and ERK activation resulting in increased breast carcinoma cell invasion. In human breast tumors, Beclin 1 expression is inversely correlated with AKT and ERK phosphorylation. Taken together my data identify a novel role for Beclin 1 in regulating growth factor signaling and reveal a mechanism by which loss of Beclin 1 expression would enhance breast cancer progression independent of its impact on autophagy.
70

Characterization of FH3-derived and MC29-derived Gag-Myc fusion proteins : correlation of transcriptional repression and protein stability with cellular transformation /

Law, Wendy. January 2000 (has links)
Thesis (Ph. D.)--University of Washington, 2000. / Vita. Includes bibliographical references (leaves 106-143).

Page generated in 0.1038 seconds